{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:56:56Z","timestamp":1787497016686,"version":"build-2736575974"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs), such as anti-programmed cell death-1 (PD-1) antibodies, have become pivotal in treating advanced cancers. While effective, they are associated with immune-related adverse events (irAEs). Ocular irAEs, including uveitis, are uncommon, and Vogt-Koyanagi-Harada (VKH)-like panuveitis is a rare but vision-threatening complication. Sintilimab is a PD-1 inhibitor used in China, and this report describes a case of VKH-like uveitis following its long-term use for gastric cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation<\/jats:title>\n                    <jats:p>A 55-year-old man presented with a 1-week history of bilateral blurred vision and tinnitus. He had been receiving sintilimab for metastatic gastric cancer over the past year. His best-corrected visual acuity (BCVA) was 0.3 (approximately 6\/20) in the right eye and 0.15 (approximately 6\/40) in the left. Ophthalmic examination revealed bilateral anterior uveitis, optic disc swelling, and peripheral choroidal detachments. Optical coherence tomography (OCT) showed retinal pigment epithelium (RPE) undulations, subretinal fluid, and choroidal thickening. Fundus Fluorescein Angiography (FFA) confirmed bilateral diffuse pinpoint leakage and late optic nerve hyper fluorescence. A diagnosis of VKH-like panuveitis was made. Sintilimab was discontinued, and treatment with topical prednisolone acetate was initiated. Within 4\u00a0weeks, the patient\u2019s BCVA improved to 0.8 in both eyes, and this improvement remained stable at the 5-month follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case suggests that long-term therapy with sintilimab, a PD-1 antibody, can trigger VKH-like uveitis. Early recognition, prompt discontinuation of the ICI, and anti-inflammatory treatment are crucial for visual recovery. It highlights the necessity for ophthalmological monitoring in cancer patients on long-term immunotherapy, even after many months of treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1857320","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T05:38:18Z","timestamp":1783316298000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case report: Vogt-Koyanagi-Harada-like uveitis induced by anti-PD-1 therapy (Sintilimab) in a gastric cancer patient: a case study"],"prefix":"10.3389","volume":"17","author":[{"given":"Lei","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Beijing Tsinghua ChangGung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Beijing Tsinghua ChangGung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Yong","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Beijing Tsinghua ChangGung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1128\/IAI.00117-10","article-title":"CD4 T-cell suppression by cells from toxoplasma gondii-infected retinas is mediated by surface protein PD-L1","volume":"78","author":"Charles","year":"2010","journal-title":"Infect. Immun."},{"key":"B2","doi-asserted-by":"publisher","first-page":"100691","DOI":"10.1016\/j.ajoc.2020.100691","article-title":"Bilateral uveitis associated with nivolumab therapy for metastatic non-small cell lung cancer","volume":"18","author":"Dermarkarian","year":"2020","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.preteyeres.2016.02.002","article-title":"Vogt-Koyanagi-Harada disease: novel insights into pathophysiology, diagnosis and treatment","volume":"52","author":"Du","year":"2016","journal-title":"Prog. Retin Eye Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1189\/jlb.0610332","article-title":"PD-L1(hi) retinal pigment epithelium (RPE) cells elicited by inflammatory cytokines induce regulatory activity in uveitogenic T cells","volume":"88","author":"Ke","year":"2010","journal-title":"J. Leukoc. Biol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e00545","DOI":"10.1002\/rcr2.545","article-title":"Vogt-Koyanagi-Harada disease during chemoimmunotherapy for non-small cell lung cancer","volume":"8","author":"Kurono","year":"2020","journal-title":"Respirol. Case Rep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000496682","article-title":"Vogt-Koyanagi-Harada disease-like uveitis during Nivolumab (Anti-PD-1 antibody) treatment for metastatic cutaneous malignant melanoma","volume":"10","author":"Obata","year":"2019","journal-title":"Case Rep. Ophthalmol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3109\/09273948.2014.1001858","article-title":"Ipilimumab-induced ocular and orbital Inflammation--A case series and review of the literature","volume":"24","author":"Papavasileiou","year":"2016","journal-title":"Ocul. Immunol. Inflamm."},{"key":"B9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1080\/09273948.2022.2159447","article-title":"Characteristics of ocular inflammatory side effects associated with immune checkpoint inhibitors in a Northern California population","volume":"32","author":"Qian","year":"2024","journal-title":"Ocul. Immunol. Inflamm."},{"key":"B11","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/cmr.0000000000000933","article-title":"Uveitis associated with immune checkpoint inhibitors or BRAF\/MEK inhibitors in patients with malignant melanoma","volume":"33","author":"Sada","year":"2023","journal-title":"Melanoma Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.autrev.2014.01.023","article-title":"Diagnosis and classification of Vogt-Koyanagi-Harada disease","volume":"13","author":"Sakata","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1080\/09273948.2023.2233015","article-title":"Diagnostic challenges in PD-1 inhibitor induced panuveitis in a teenage girl with chest soft tissue sarcoma - a case report","volume":"31","author":"Shen","year":"2023","journal-title":"Ocul. Immunol. Inflamm."},{"key":"B15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1167\/iovs.08-2536","article-title":"Human corneal endothelial cells expressing programmed death-ligand 1 (PD-L1) suppress PD-1+ T helper 1 cells by a contact-dependent mechanism","volume":"50","author":"Sugita","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"6926","DOI":"10.1167\/iovs.13-12703","article-title":"Suppression of IL-22-producing T helper 22 cells by RPE cells via PD-L1\/PD-1 interactions","volume":"54","author":"Sugita","year":"2013","journal-title":"Invest. Ophthal. Vis. Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"13580","DOI":"10.1038\/s41598-023-40565-z","article-title":"HLA-DRB1*04:05 is involved in the development of Vogt-Koyanagi-Harada disease-like immune-related adverse events in patients receiving immune checkpoint inhibitors","volume":"13","author":"Takeuchi","year":"2023","journal-title":"Sci. Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12886-024-03484-9","article-title":"Development of Vogt-Koyanagi-Harada disease-like uveitis during treatment by anti-programmed death-1 antibody: a case report","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Ophthalmol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"key":"B20","doi-asserted-by":"publisher","first-page":"701951","DOI":"10.3389\/fimmu.2021.701951","article-title":"Ocular immune-related adverse events associated with immune checkpoint inhibitors in lung cancer","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Immunol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1857320\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T05:38:24Z","timestamp":1783316304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1857320\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":20,"alternative-id":["10.3389\/fphar.2026.1857320"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1857320","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"article-number":"1857320"}}